Viaderma Inc (OTCMKTS:VDRM) shares were up 34.62% on Thursday and an additional 40.57% in after-hours trading to $0.00492. Share prices have been trading in a 52-week range of $0.00 to $0.02. The company has a market cap of $552,395.00 at 200.32 million shares outstanding.
Viaderma Inc is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. It licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. Its products are applied topically using a delivery system technology and are are used within the over-the-counter market.
In addition to the primary plan of developing and selling new products to the market, Viaderma Inc is exploring the possibility of licensing the technology to other pharmaceutical companies. It has products in development in various fields, including topical antibiotics TetraStem, topical anti-viral product Viralcur for genital herpes, anti-fungal products for onychomycocis OnyPro, hair loss prevention product HairGain, skin cancer therapies Cantrile, and a topical stem cell therapy product TetraStem Plus.
Earlier in the week, Viaderma Inc announced the Patent Pending use of its innovative transdermal system for the delivery of Calanoids and Tetrahydrocannabinol for the treatment of several diseases. This marks the company’s venture in the booming cannabis market, which is poised to reach $20 billion by 2020 following the November 8 vote which legalized the use of medical or recreational marijuana in several states. This transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream.
We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community,” said Dr. Christopher Otiko, Viaderma Inc founder and CEO.
The following day, Viaderma Inc announced that several patients have had significant treatment success with the use of its innovative transdermal system for the delivery of its FDA-registered drug, Viabecline. This drug is a topical liquid tetracycline-based antibiotic that uses the transdermal delivery system that can convert oral medication active ingredients into topical drugs. It is registered as a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. It has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections.
We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community. We are also in early-stage discussion with two companies to private label Viabecline for distribution in the Middle East, Asia and North Africa, and Europe,” said Dr. Otiko.
These results have been achieved in just 10 days of treatment using the company’s proprietary transdermal system. When combined with other FDA-registered drugs, the system can increase the absorption as much as 100 times directly to the localized treatment areas.
“We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido,” added Dr. Otiko.
If all goes well with the company’s patent and distribution of Viablcine in other markets, Viaderma Inc shares could continue to enjoy more upside, in addition to potentially strong returns in its cannabis market venture down the line.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.